Prognostic model predicts breast cancer outcomes and identifies patients for immunotherapy, suggesting individualized treatments.
This study constructed and validated a reliable BCa prognosis model based on NMRGs. The model has a good ability for prognosis stratification, showing great potential to serve as an auxiliary tool for identifying patients who benefit from immunotherapy. These findings provide a new strategy for individualized immunotherapy of BCa.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: